flow trial semaglutide kidney outcomes hazard ratio 0.76 nejm 2024 Long-term of in obesity and cardiovascular disease in the SELECT Semaglutide in Patients with Heart
Description
That being said, more extensive studies should be conducted to assess its effect on a larger patient population and its long-term safety for patients with HNF1B-MODY
[DOI] [PubMed] [Google Scholar] 40.Zhang HD, Ding L, Liu K, et al
J.G.None
White, G
Researcher Liabilities : Understanding local laws helps researchers mitigate risks associated with non-compliance
